News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
569,450 Results
Type
Article (15123)
Company Profile (149)
Press Release (554176)
Multimedia
Podcasts (19)
Webinars (13)
Section
Business (194619)
Career Advice (650)
Deals (29351)
Drug Delivery (31)
Drug Development (61620)
Employer Resources (62)
FDA (11536)
Job Trends (10336)
News (278300)
Policy (21937)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (1186)
Accelerated approval (37)
ADA (25)
Adcomms (15)
Allergies (129)
Alliances (38867)
ALS (140)
Alzheimer's disease (1277)
Antibody-drug conjugate (ADC) (366)
Approvals (12208)
Artificial intelligence (472)
ASCO (195)
Autoimmune disease (244)
Automation (36)
Bankruptcy (290)
Best Places to Work (8331)
BIO (76)
Biologics (2)
BIOSECURE Act (4)
Biosimilars (146)
BioSpace Insights (48)
Biotechnology (93)
Bladder cancer (144)
Brain cancer (42)
Breast cancer (592)
Cancer (4541)
Cardiovascular disease (286)
Career advice (554)
Career pathing (16)
CAR-T (218)
CDC (9)
Celiac Disease (2)
Cell therapy (597)
Cervical cancer (42)
Clinical research (55535)
Collaboration (1596)
Commercialization (3)
Compensation (1487)
Complete response letters (48)
COVID-19 (1159)
CRISPR (76)
C-suite (985)
Cystic fibrosis (109)
Data (6828)
Decentralized trials (1)
Denatured (11)
Depression (115)
Dermatology (81)
Diabetes (446)
Diagnostics (5222)
Digital health (50)
Diversity (2)
Diversity, equity & inclusion (17)
Drug discovery (230)
Drug pricing (36)
Drug shortages (3)
Duchenne muscular dystrophy (194)
Earnings (85161)
Editorial (11)
Employer branding (9)
Employer resources (60)
Events (99955)
Executive appointments (867)
FDA (14658)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (18)
Frontotemporal dementia (29)
Funding (1170)
Gene editing (148)
Generative AI (27)
Gene therapy (414)
GLP-1 (438)
Government (1808)
Grass and pollen (3)
Guidances (349)
Healthcare (12046)
Hematology (124)
HIV (73)
Huntington's disease (31)
IgA nephropathy (84)
Immunology and inflammation (124)
Immuno-oncology (72)
Indications (189)
Infectious disease (1401)
Inflammatory bowel disease (153)
Inflation Reduction Act (4)
Influenza (109)
Intellectual property (283)
Interviews (93)
IPO (14171)
IRA (5)
Job creations (2391)
Job search strategy (503)
JPM (9)
Kidney cancer (21)
Labor market (15)
Layoffs (143)
Leadership (12)
Legal (5807)
Licensing (8)
Liver cancer (55)
Longevity (23)
Lung cancer (652)
Lymphoma (342)
Machine learning (39)
Management (23)
Manufacturing (712)
Marketing (10)
MASH (146)
Medical device (10442)
Medtech (10610)
Mergers & acquisitions (16326)
Metabolic disorders (938)
mRNA (80)
Multiple sclerosis (121)
NASH (4)
Neurodegenerative disease (309)
Neuropsychiatric disorders (49)
Neuroscience (2366)
NextGen: Class of 2026 (3986)
Non-profit (1928)
Now hiring (8)
Obesity (326)
Opinion (74)
Ovarian cancer (185)
Pain (201)
Pancreatic cancer (243)
Parkinson's disease (284)
Partnered (18)
Patents (519)
Patient recruitment (600)
Peanut (45)
People (49173)
Pharmaceutical (36)
Pharmacy benefit managers (8)
Phase 1 (17474)
Phase 2 (24548)
Phase 3 (17400)
Pipeline (8758)
Policy (74)
Postmarket research (1967)
Preclinical (7471)
Press Release (47)
Prostate cancer (245)
Psychedelics (12)
Radiopharmaceuticals (245)
Rare diseases (718)
Real estate (3880)
Recruiting (27)
Regulatory (18269)
Reports (27)
Research institute (1159)
Resumes & cover letters (88)
Rett syndrome (44)
RNA editing (9)
RSV (55)
Schizophrenia (129)
Series A (193)
Series B (155)
Service/supplier (5)
Sickle cell disease (76)
Spinal muscular atrophy (98)
Sponsored (20)
Startups (2434)
Stomach cancer (8)
Supply chain (67)
Tariffs (18)
The Weekly (8)
Vaccines (515)
Venture capital (38)
Weight loss (135)
Women's health (94)
Worklife (6)
Date
Last 7 days (282)
Last 30 days (1844)
Last 365 days (22670)
2026 (14822)
2025 (22558)
2024 (26600)
2023 (30914)
2022 (39686)
2021 (42872)
2020 (39577)
2019 (30248)
2018 (22869)
2017 (23508)
2016 (22605)
2015 (29227)
2014 (25165)
2013 (21158)
2012 (23255)
2011 (23794)
2010 (22979)
Location
Africa (434)
Alabama (78)
Alaska (2)
Arizona (332)
Arkansas (11)
Asia (27645)
Australia (4136)
California (12645)
Canada (3396)
China (1061)
Colorado (515)
Connecticut (451)
Delaware (262)
Europe (50803)
Florida (1948)
Georgia (400)
Hawaii (4)
Idaho (47)
Illinois (850)
India (78)
Indiana (437)
Iowa (17)
Japan (535)
Kansas (118)
Kentucky (33)
Louisiana (36)
Maine (78)
Maryland (1366)
Massachusetts (8725)
Michigan (340)
Minnesota (650)
Mississippi (4)
Missouri (109)
Montana (22)
Nebraska (17)
Nevada (123)
New Hampshire (68)
New Jersey (3100)
New Mexico (17)
New York (3099)
North Carolina (1464)
North Dakota (6)
Northern California (6325)
Ohio (328)
Oklahoma (20)
Oregon (22)
Pennsylvania (2404)
Puerto Rico (22)
Rhode Island (31)
South America (709)
South Carolina (77)
South Dakota (1)
Southern California (5228)
Tennessee (135)
Texas (2101)
United States (42772)
Utah (377)
Vermont (1)
Virginia (186)
Washington D.C. (46)
Washington State (979)
West Virginia (1)
Wisconsin (103)
Wyoming (3)
569,450 Results for "dyadic international inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
August 12, 2026
·
12 min read
Press Releases
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
July 16, 2026
·
6 min read
Press Releases
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
May 19, 2026
·
3 min read
Press Releases
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
May 28, 2026
·
8 min read
Press Releases
Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
July 3, 2025
·
5 min read
Business
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the diagnostic, nutrition and cell culture markets.
June 28, 2024
·
4 min read
Dyadic to Present at BioProcess International
Dyadic International, Inc. today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.
September 12, 2023
·
3 min read
Press Releases
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
November 13, 2025
·
15 min read
Press Releases
Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
October 29, 2025
·
2 min read
Business
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced its financial results for the first quarter of 2024 and highlighted recent Company progress.
May 14, 2024
·
21 min read
1 of 56,945
Next
